HR 2497 108th Congress House Health Administrative procedure Canada Commerce Congress Congressional investigations Congressional reporting requirements Consumer protection Department of Health and Human Services Drug approvals Drug industry Drugs Foreign Trade and International Finance Government Operations and Politics Government paperwork Governmental investigations Identification devices Import restrictions Imports Intellectual property

Prescription Drug Parity for Americans Act

Introduced: June 17, 2003 Introduced by: Sanders, Bernard Independent · Vermont See on congress.gov

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Jun 24, 2003

Referred to the Subcommittee on Health.

Jun 17, 2003

Referred to the House Committee on Energy and Commerce.

Jun 17, 2003

Introduced in House

Plain-English summary Congressional Research Service

Prescription Drug Parity for Americans Act - Amends provisions of the Federal Food, Drug, and Cosmetic Act set forth in the Medicine Equity and Drug Safety Act of 2000 to: (1) direct the Secretary of Health and Human Services to promulgate regulations permitting pharmacists and wholesalers to import Food and Drug Administration (FDA)-approved prescription drugs from Canada (currently, from Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, the countries in the European Union and the European Free Trade Association, or other countries designated by the Secretary); and (2) exclude an infused or intravenously injected drug or a drug that is inhaled during surgery.

Prohibits discrimination in the sale of prescription drugs by manufacturers to pharmacists or wholesalers, requiring: (1) terms as favorable as those provided to foreign purchasers; and (2) full access to drugs permitted to be imported.

Continues the requirement that exported donated prescription drugs may only be reimported by the manufacturer.

Permits the Secretary to waive the prohibition against importing a prescription drug or device on a case-by-case basis, particularly those from Canada that are FDA-approved and for limited personal use.

Requires a study and report by the: (1) Institute of Medicine of the National Academy of Sciences on the regulatory compliance of importers of drugs; and (2) Comptroller General on how drug prices were affected.

What's happening now June 24, 2003

Referred to the Subcommittee on Health.

Committees of jurisdiction 2